Showing results (101-110 of 138) with videos related to
Sort By:
Pageof 14
Immunity|September 30, 2022
Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized miceEleonora Melzi, Jordan R Willis, Krystal M Ma, et al.Immunity|July 21, 2016
A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging GlycansDevin Sok, Matthias Pauthner, Bryan Briney, et al.Immunity|November 23, 2017
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody LineageElise Landais, Ben Murrell, Bryan Briney, et al.Plos Pathogens|January 15, 2016
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortElise Landais, Xiayu Huang, Colin Havenar-Daughton, et al.Plos Pathogens|August 26, 2016
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine DesignJoseph G Jardine, Devin Sok, Jean-Philippe Julien, et al.Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling studyChristopher Alba, Shelly Malhotra, Stephanie Horsfall, et al.Plos Pathogens|September 15, 2016
Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine DesignJoseph G Jardine, Devin Sok, Jean-Philippe Julien, et al.Microbiology Spectrum|March 22, 2023
Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization BreadthSuprit Deshpande, Mohammed Yousuf Ansari, Jyoti Sutar, et al.Mabs|March 5, 2014
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAJuan Carlos Almagro, Gary L Gilliland, Felix Breden, et al.Nature Communications|March 7, 2024
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteriaStian Foss, Siri A Sakya, Leire Aguinagalde, et al.Pageof 14